{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T15:56:48Z","timestamp":1747151808713,"version":"3.40.5"},"reference-count":39,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T00:00:00Z","timestamp":1599436800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmaceutical Statistics"],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Composite endpoints reveal the tendency for statistical convention to arise locally within subfields. Composites are familiar in cardiovascular trials, yet almost unknown in sepsis. However, the VITAMINS trial in patients with septic shock adopted a composite of mortality and vasopressor\u2010free days, and an ordinal scale describing patient status rapidly became standard in COVID studies. Aware that recent use could incite interest in such endpoints, we are motivated to flag their potential value and pitfalls for sepsis research and COVID studies.<\/jats:p>","DOI":"10.1002\/pst.2070","type":"journal-article","created":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T07:57:53Z","timestamp":1600329473000},"page":"413-417","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The promise and pitfalls of composite endpoints in sepsis and <scp>COVID<\/scp>\u201019 clinical trials"],"prefix":"10.1002","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2411-3312","authenticated-orcid":false,"given":"P. M.","family":"Brown","sequence":"first","affiliation":[{"name":"Gemini Center for Sepsis Research Clinic of Anesthesia and Intensive Care, St. Olav's hospital, Trondheim University Hospital  Trondheim Norway"},{"name":"Department of Clinical and Molecular Medicine Norwegian University of Science and Technology  Trondheim Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tormod","family":"Rogne","sequence":"additional","affiliation":[{"name":"Gemini Center for Sepsis Research Clinic of Anesthesia and Intensive Care, St. Olav's hospital, Trondheim University Hospital  Trondheim Norway"},{"name":"Department of Circulation and Medical Imaging Norwegian University of Science and Technology  Trondheim Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Sollig\u00e5rd","sequence":"additional","affiliation":[{"name":"Gemini Center for Sepsis Research Clinic of Anesthesia and Intensive Care, St. Olav's hospital, Trondheim University Hospital  Trondheim Norway"},{"name":"Department of Circulation and Medical Imaging Norwegian University of Science and Technology  Trondheim Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,9,7]]},"reference":[{"key":"e_1_2_3_2_1","unstructured":"WHO R&D blueprint novel coronavirus (COVID\u201019) therapeutic trial synopsis. World Health Organization2020Web site.https:\/\/www.who.int\/blueprint\/priority-diseases\/key-action\/COVID-19_Treatment_Trial_Design_Master_Protocol_synopsis_Final_18022020.pdfPublished February 18 2020. Accessed August 11 2020."},{"key":"e_1_2_3_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-99389-8_1"},{"key":"e_1_2_3_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40560-016-0151-6"},{"key":"e_1_2_3_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19990615)18:11<1341::AID-SIM129>3.0.CO;2-7"},{"key":"e_1_2_3_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.22176"},{"key":"e_1_2_3_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000004104"},{"key":"e_1_2_3_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-020-05934-6"},{"key":"e_1_2_3_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.11825"},{"key":"e_1_2_3_10_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.114.000346"},{"key":"e_1_2_3_11_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.109.926030"},{"key":"e_1_2_3_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c3920"},{"key":"e_1_2_3_13_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.117.004419"},{"key":"e_1_2_3_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.10.051"},{"key":"e_1_2_3_15_1","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/9781118596005.ch21","volume-title":"Methods and Applications of Statistics in Clinical Trials","author":"O'Brien PC","year":"2014"},{"key":"e_1_2_3_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0197-2456(97)00008-1"},{"key":"e_1_2_3_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780140402"},{"key":"e_1_2_3_18_1","unstructured":"Guideline on clinical investigation of medicinal products for the treatment of acute heart failure. Committee for Medicinal Products for Human Use (CHMP). CPMP\/EWP\/2986\/03 Rev. 1 Web site.https:\/\/www.ema.europa.eu\/en\/clinical-investigation-medicinal-products-treatment-acute-heart-failure. Accessed February 25 2020."},{"key":"e_1_2_3_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912613"},{"key":"e_1_2_3_20_1","unstructured":"Guideline on multiplicity issues in clinical trials. European Medicines Agency. Committee for Medicinal Products for Human Use (CHM). EMA\/CHMP\/44762\/2017 Web site.https:\/\/www.ema.europa.eu\/documents\/scientific-guideline\/draft-guideline-multiplicity-issues-clinical-trials_en.pdf. Published December 15 2016. Accessed February 25 2020."},{"key":"e_1_2_3_21_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.026767"},{"key":"e_1_2_3_22_1","unstructured":"CraigP DieppeP MacintyreS MichieS NazarethIMP. Developing and evaluating complex interventions: new guidance. Medical Research Council.https:\/\/www.mrc.ac.uk\/documents\/pdf\/complex-interventions-guidance\/. Published 2006. Accessed June 12 2020."},{"key":"e_1_2_3_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-019-00517-2"},{"key":"e_1_2_3_24_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.116.003382"},{"key":"e_1_2_3_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2013.12.007"},{"key":"e_1_2_3_26_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S153196"},{"key":"e_1_2_3_27_1","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0b013e31821796d3"},{"key":"e_1_2_3_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-005330"},{"key":"e_1_2_3_29_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0063831"},{"key":"e_1_2_3_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/pst.90"},{"key":"e_1_2_3_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/pst.107"},{"key":"e_1_2_3_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31022-9"},{"key":"e_1_2_3_33_1","unstructured":"HerperM.Inside the NIH's controversial decision to stop its big remdesivir study. STAT Web site.https:\/\/www.statnews.com\/2020\/05\/11\/inside-the-nihs-controversial-decision-to-stop-its-big-remdesivir-study\/. Published May 11 2020. Accessed July 2 2020."},{"key":"e_1_2_3_34_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.16349"},{"key":"e_1_2_3_35_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.16337"},{"key":"e_1_2_3_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100403"},{"key":"e_1_2_3_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2016.02.067"},{"key":"e_1_2_3_38_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.112.969154"},{"key":"e_1_2_3_39_1","unstructured":"ICH E9 (R1) addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials. EMA\/CHMP\/ICH\/436221\/2017 Web site.https:\/\/www.ema.europa.eu\/documents\/scientific-guideline\/ich-e9-r1-addendum-estimands-sensitivity-analysis-clinical-trials-guideline-statistical-principles_en.pdf. Published February 17 2020. Accessed February 12 2020."},{"key":"e_1_2_3_40_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-020068"}],"container-title":["Pharmaceutical Statistics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpst.2070","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pst.2070","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pst.2070","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pst.2070","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T21:59:41Z","timestamp":1693691981000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pst.2070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,7]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["10.1002\/pst.2070"],"URL":"https:\/\/doi.org\/10.1002\/pst.2070","archive":["Portico"],"relation":{},"ISSN":["1539-1604","1539-1612"],"issn-type":[{"type":"print","value":"1539-1604"},{"type":"electronic","value":"1539-1612"}],"subject":[],"published":{"date-parts":[[2020,9,7]]},"assertion":[{"value":"2020-04-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}